Literature DB >> 2839723

Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.

L E Perryman1, K I O'Rourke, T C McGuire.   

Abstract

Six normal and four immunodeficient horses were injected with a cloned variant of equine infectious anemia virus (EIAV). The six normal horses had detectable EIAV in their plasma by 7 days postinjection. During their primary viremic episode, which was accompanied by fever and anemia, maximum titers of EIAV in plasma ranged from 10(3.8) to 10(4.8) 50% tissue culture infective doses per ml. All six normal horses cleared detectable virus from their plasma by 21 to 35 days after injection. Horses with combined immunodeficiency became viremic by 9 days postinjection and also developed anemia. In contrast to normal horses, foals with combined immunodeficiency did not eliminate the virus from their plasma.

Entities:  

Mesh:

Year:  1988        PMID: 2839723      PMCID: PMC253753          DOI: 10.1128/JVI.62.8.3073-3076.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Large granular lymphocytes from SCID horses develop potent cytotoxic activity after treatment with human recombinant interleukin 2.

Authors:  N S Magnuson; L E Perryman; C R Wyatt; P H Mason; J E Talmadge
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

Review 2.  Pathogenesis of lentivirus infections.

Authors:  A T Haase
Journal:  Nature       Date:  1986 Jul 10-16       Impact factor: 49.962

3.  Complement (C'3)-coated red blood cells following infection with the virus of equine infectious anemia.

Authors:  T C McGuire; J B Henson; D Burger
Journal:  J Immunol       Date:  1969-08       Impact factor: 5.422

4.  Viral-induced hemolysis in equine infectious anemia.

Authors:  T C McGuire; J B Henson; S E Quist
Journal:  Am J Vet Res       Date:  1969-12       Impact factor: 1.156

5.  Impaired bone marrow response in equine infectious anemia.

Authors:  T C McGuire; J B Henson; S E Quist
Journal:  Am J Vet Res       Date:  1969-12       Impact factor: 1.156

6.  Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.

Authors:  K O'Rourke; L E Perryman; T C McGuire
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

7.  Defective thymocyte maturation in horses with severe combined immunodeficiency.

Authors:  C R Wyatt; N S Magnuson; L E Perryman
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

8.  Molecular cloning of integrated caprine arthritis-encephalitis virus.

Authors:  A Yaniv; J E Dahlberg; S R Tronick; I M Chiu; S A Aaronson
Journal:  Virology       Date:  1985-09       Impact factor: 3.616

9.  Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses.

Authors:  I M Chiu; A Yaniv; J E Dahlberg; A Gazit; S F Skuntz; S R Tronick; S A Aaronson
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

10.  Equine alternative pathway activation by unsensitized rabbit red blood cells.

Authors:  R W Leid; S C Coley; D P Blanchard; L E Perryman
Journal:  Vet Immunol Immunopathol       Date:  1985-05       Impact factor: 2.046

View more
  42 in total

Review 1.  Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Authors:  R J Miller; J S Cairns; S Bridges; N Sarver
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.

Authors:  S T Perry; M T Flaherty; M J Kelley; D L Clabough; S R Tronick; L Coggins; L Whetter; C R Lengel; F Fuller
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

3.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

4.  Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.

Authors:  S M Harrold; S J Cook; R F Cook; K E Rushlow; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Analysis of equine humoral immune responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus.

Authors:  Y H Chong; J M Ball; C J Issel; R C Montelaro; K E Rushlow
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

6.  Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.

Authors:  Sandra D Taylor; Steven R Leib; Wuwei Wu; Robert Nelson; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

7.  Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

Authors:  J Meers; G M del Fierro; R B Cope; H S Park; W K Greene; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

8.  Proviral sequences detected by polymerase chain reaction in peripheral blood cells of horses with equine infectious anemia lentivirus.

Authors:  K I O'Rourke; M L Besola; T C McGuire
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

9.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Feline immunodeficiency virus: quantification in peripheral blood mononuclear cells and isolation from plasma of infected cats.

Authors:  J Meers; W F Robinson; G M del Fierro; M A Scoones; M A Lawson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.